oBservational clinical Research In chronic kidney disease patients with renal anemia :renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis stimulating agents,darbepoetiN alfa
Phase of Trial: Phase IV
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms BRIGHTEN
- 26 Sep 2019 Status changed from active, no longer recruiting to completed.
- 13 Sep 2018 Planned End Date changed from 1 Mar 2018 to 1 Sep 2019.
- 13 Sep 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2019.